SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Nortran's potential blockbuster heart drug
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Pat Sims who wrote (11)12/27/1996 12:11:00 PM
From: xray   of 27
 
I would be able to comment if there were more information available at the website, but I could only find a brief reference to Quadramet in a news release:

"Quadramet (153Samarium-EDTMP) is a therapeutic radiopharmaceutical that targets actively forming bone and concentrates in areas that have been invaded by cancer."

From this, the selectivity of Quadramet for metastatic bone is evident. No other pharmacological or toxicological information is given.

RSD921 and RSD931 are of two different classes of analgesic. The former is a local anaesthetic, the latter a selective nociceptor blocker. Both potential drugs show therapeutic indices (efficacy to toxicity ratios) that stimulate our continued support of preclinical and clinical work with both compounds. Both also have pharmacokinetic profiles which are conducive to certain therapeutic applications. For more discussion, please watch for scientific updates to our website nortran.com or call us at 800-330-9928.

Thanks, AB
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News